SILO PHARMA INC. - COMMON STOCK

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

21 مايو 2025 05:55:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Closing of $2 Million Public Offering

16 مايو 2025 13:15:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Pricing of $2 Million Public Offering

15 مايو 2025 06:15:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

14 مايو 2025 13:07:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

14 مايو 2025 05:40:00 بحسب Nasdaq GlobeNewswire

Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

30 أبريل 2025 05:11:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug

28 أبريل 2025 04:50:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

26 مارس 2025 05:40:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

26 فبراير 2025 10:30:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

18 فبراير 2025 05:50:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

11 فبراير 2025 04:45:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

22 يناير 2025 05:29:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

08 يناير 2025 05:29:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

02 يناير 2025 05:45:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

18 ديسمبر 2024 04:35:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

29 نوفمبر 2024 05:05:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

18 نوفمبر 2024 05:40:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

31 أكتوبر 2024 05:35:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

10 سبتمبر 2024 03:35:00 بحسب Nasdaq GlobeNewswire

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

14 أغسطس 2024 11:30:00 بحسب Nasdaq GlobeNewswire